UK markets open in 6 hours 10 minutes
  • NIKKEI 225

    28,752.89
    +297.29 (+1.04%)
     
  • HANG SENG

    24,018.11
    +34.45 (+0.14%)
     
  • CRUDE OIL

    71.71
    -0.34 (-0.47%)
     
  • GOLD FUTURES

    1,786.90
    +2.20 (+0.12%)
     
  • DOW

    35,719.43
    +492.40 (+1.40%)
     
  • BTC-GBP

    38,097.36
    -375.79 (-0.98%)
     
  • CMC Crypto 200

    1,304.24
    -17.04 (-1.29%)
     
  • ^IXIC

    15,686.92
    +461.76 (+3.03%)
     
  • ^FTAS

    4,178.76
    +61.16 (+1.49%)
     

Moderna to Present at Upcoming Investor Conferences in November 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., October 28, 2021--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

  • Bernstein Operational Decisions Conference on Thursday, November 4, 2021 at 4:30 p.m. ET

  • Credit Suisse 30th Annual Healthcare Conference on Monday, November 8, 2021 at 1:50 p.m. ET

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna’s website for at least 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211028006164/en/

Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting